nodes	percent_of_prediction	percent_of_DWPC	metapath
Salicylic acid—PTGS2—bone cancer	0.419	1	CbGaD
Salicylic acid—SLC16A1—Methotrexate—bone cancer	0.151	0.277	CbGbCtD
Salicylic acid—SLC22A11—Methotrexate—bone cancer	0.078	0.143	CbGbCtD
Salicylic acid—SLC22A7—Methotrexate—bone cancer	0.0743	0.136	CbGbCtD
Salicylic acid—PTGS2—Cisplatin—bone cancer	0.0657	0.12	CbGbCtD
Salicylic acid—SLC22A8—Methotrexate—bone cancer	0.0454	0.0831	CbGbCtD
Salicylic acid—SLC22A6—Methotrexate—bone cancer	0.0316	0.0579	CbGbCtD
Salicylic acid—ALB—Methotrexate—bone cancer	0.0269	0.0493	CbGbCtD
Salicylic acid—CYP2C9—Cisplatin—bone cancer	0.0223	0.0409	CbGbCtD
Salicylic acid—ABCB1—Cisplatin—bone cancer	0.0217	0.0397	CbGbCtD
Salicylic acid—ABCB1—Doxorubicin—bone cancer	0.0145	0.0266	CbGbCtD
Salicylic acid—ABCB1—Methotrexate—bone cancer	0.0141	0.0258	CbGbCtD
Salicylic acid—AKR1C1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00223	0.133	CbGpPWpGaD
Salicylic acid—Acetylsalicylic acid—TP53—bone cancer	0.00195	0.287	CrCbGaD
Salicylic acid—AKR1C1—Metapathway biotransformation—CYP4V2—bone cancer	0.00105	0.0628	CbGpPWpGaD
Salicylic acid—Salicylate-sodium—PTGS2—bone cancer	0.000876	0.129	CrCbGaD
Salicylic acid—SLCO2B1—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.000768	0.0461	CbGpPWpGaD
Salicylic acid—Magnesium salicylate—PTGS2—bone cancer	0.000601	0.0885	CrCbGaD
Salicylic acid—Diflunisal—PTGS2—bone cancer	0.000565	0.0832	CrCbGaD
Salicylic acid—Aminosalicylic Acid—PTGS2—bone cancer	0.000565	0.0832	CrCbGaD
Salicylic acid—Salsalate—PTGS2—bone cancer	0.000511	0.0752	CrCbGaD
Salicylic acid—Meclofenamic acid—PTGS2—bone cancer	0.000503	0.0742	CrCbGaD
Salicylic acid—SLC22A7—Fluoropyrimidine Activity—DHFR—bone cancer	0.000479	0.0287	CbGpPWpGaD
Salicylic acid—SLC16A1—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.000466	0.0279	CbGpPWpGaD
Salicylic acid—Mesalazine—PTGS2—bone cancer	0.000443	0.0653	CrCbGaD
Salicylic acid—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000403	0.0242	CbGpPWpGaD
Salicylic acid—Mefenamic acid—PTGS2—bone cancer	0.000391	0.0577	CrCbGaD
Salicylic acid—Hearing impaired—Cisplatin—bone cancer	0.000387	0.0316	CcSEcCtD
Salicylic acid—Pain—Carboplatin—bone cancer	0.000384	0.0313	CcSEcCtD
Salicylic acid—Acetylsalicylic acid—PTGS2—bone cancer	0.000381	0.0562	CrCbGaD
Salicylic acid—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000377	0.0226	CbGpPWpGaD
Salicylic acid—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000377	0.0226	CbGpPWpGaD
Salicylic acid—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000375	0.0225	CbGpPWpGaD
Salicylic acid—ALB—Folate Metabolism—FOLR1—bone cancer	0.000366	0.0219	CbGpPWpGaD
Salicylic acid—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000358	0.0215	CbGpPWpGaD
Salicylic acid—Skin exfoliation—Cisplatin—bone cancer	0.000352	0.0287	CcSEcCtD
Salicylic acid—Gastric ulcer—Epirubicin—bone cancer	0.000326	0.0266	CcSEcCtD
Salicylic acid—Gastric ulcer—Doxorubicin—bone cancer	0.000302	0.0246	CcSEcCtD
Salicylic acid—Deafness—Cisplatin—bone cancer	0.000299	0.0244	CcSEcCtD
Salicylic acid—Burning sensation—Methotrexate—bone cancer	0.000291	0.0238	CcSEcCtD
Salicylic acid—Burning sensation—Epirubicin—bone cancer	0.000273	0.0222	CcSEcCtD
Salicylic acid—Burning sensation—Doxorubicin—bone cancer	0.000252	0.0206	CcSEcCtD
Salicylic acid—Stinging—Epirubicin—bone cancer	0.000234	0.0191	CcSEcCtD
Salicylic acid—Abdominal discomfort—Cisplatin—bone cancer	0.000222	0.0181	CcSEcCtD
Salicylic acid—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000221	0.0132	CbGpPWpGaD
Salicylic acid—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000217	0.013	CbGpPWpGaD
Salicylic acid—Stinging—Doxorubicin—bone cancer	0.000216	0.0176	CcSEcCtD
Salicylic acid—AKR1C1—Metapathway biotransformation—CYP3A4—bone cancer	0.000207	0.0124	CbGpPWpGaD
Salicylic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000203	0.0122	CbGpPWpGaD
Salicylic acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000203	0.0122	CbGpPWpGaD
Salicylic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000203	0.0121	CbGpPWpGaD
Salicylic acid—Skin exfoliation—Methotrexate—bone cancer	0.000193	0.0158	CcSEcCtD
Salicylic acid—Ecchymosis—Methotrexate—bone cancer	0.000183	0.0149	CcSEcCtD
Salicylic acid—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000181	0.0108	CbGpPWpGaD
Salicylic acid—Skin exfoliation—Epirubicin—bone cancer	0.000181	0.0147	CcSEcCtD
Salicylic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000179	0.0107	CbGpPWpGaD
Salicylic acid—AKR1C1—Metapathway biotransformation—GSTP1—bone cancer	0.000177	0.0106	CbGpPWpGaD
Salicylic acid—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000174	0.0104	CbGpPWpGaD
Salicylic acid—Oesophagitis—Epirubicin—bone cancer	0.000173	0.0141	CcSEcCtD
Salicylic acid—Tinnitus—Cisplatin—bone cancer	0.000173	0.0141	CcSEcCtD
Salicylic acid—Ecchymosis—Epirubicin—bone cancer	0.000171	0.014	CcSEcCtD
Salicylic acid—Skin exfoliation—Doxorubicin—bone cancer	0.000167	0.0136	CcSEcCtD
Salicylic acid—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000161	0.00967	CbGpPWpGaD
Salicylic acid—Erythema—Cisplatin—bone cancer	0.000161	0.0132	CcSEcCtD
Salicylic acid—Oesophagitis—Doxorubicin—bone cancer	0.00016	0.0131	CcSEcCtD
Salicylic acid—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000159	0.00953	CbGpPWpGaD
Salicylic acid—Ecchymosis—Doxorubicin—bone cancer	0.000158	0.0129	CcSEcCtD
Salicylic acid—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.00015	0.009	CbGpPWpGaD
Salicylic acid—Lethargy—Methotrexate—bone cancer	0.00015	0.0122	CcSEcCtD
Salicylic acid—Lethargy—Epirubicin—bone cancer	0.00014	0.0114	CcSEcCtD
Salicylic acid—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000133	0.00797	CbGpPWpGaD
Salicylic acid—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000132	0.0079	CbGpPWpGaD
Salicylic acid—Oedema—Cisplatin—bone cancer	0.000132	0.0107	CcSEcCtD
Salicylic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000131	0.00787	CbGpPWpGaD
Salicylic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.00013	0.00782	CbGpPWpGaD
Salicylic acid—Lethargy—Doxorubicin—bone cancer	0.00013	0.0106	CcSEcCtD
Salicylic acid—Asthma—Methotrexate—bone cancer	0.000127	0.0104	CcSEcCtD
Salicylic acid—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000127	0.0076	CbGpPWpGaD
Salicylic acid—AKR1C1—Metabolism—NDUFA12—bone cancer	0.000126	0.00755	CbGpPWpGaD
Salicylic acid—Abdominal pain upper—Epirubicin—bone cancer	0.000126	0.0102	CcSEcCtD
Salicylic acid—Anorexia—Cisplatin—bone cancer	0.000125	0.0102	CcSEcCtD
Salicylic acid—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000124	0.00745	CbGpPWpGaD
Salicylic acid—Abdominal discomfort—Methotrexate—bone cancer	0.000122	0.00993	CcSEcCtD
Salicylic acid—Asthma—Epirubicin—bone cancer	0.000119	0.00969	CcSEcCtD
Salicylic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000118	0.0071	CbGpPWpGaD
Salicylic acid—Abdominal pain upper—Doxorubicin—bone cancer	0.000116	0.00948	CcSEcCtD
Salicylic acid—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000116	0.00695	CbGpPWpGaD
Salicylic acid—Decreased appetite—Cisplatin—bone cancer	0.000114	0.00933	CcSEcCtD
Salicylic acid—Drowsiness—Methotrexate—bone cancer	0.000113	0.00923	CcSEcCtD
Salicylic acid—Pain—Cisplatin—bone cancer	0.000113	0.00918	CcSEcCtD
Salicylic acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00011	0.00661	CbGpPWpGaD
Salicylic acid—Asthma—Doxorubicin—bone cancer	0.00011	0.00897	CcSEcCtD
Salicylic acid—Feeling abnormal—Cisplatin—bone cancer	0.000108	0.00884	CcSEcCtD
Salicylic acid—Weight increased—Epirubicin—bone cancer	0.000108	0.00882	CcSEcCtD
Salicylic acid—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000107	0.00642	CbGpPWpGaD
Salicylic acid—Epistaxis—Methotrexate—bone cancer	0.000107	0.00871	CcSEcCtD
Salicylic acid—Drowsiness—Epirubicin—bone cancer	0.000106	0.00864	CcSEcCtD
Salicylic acid—AKR1C1—Metabolism—NT5C3A—bone cancer	0.000104	0.00626	CbGpPWpGaD
Salicylic acid—Hepatitis—Methotrexate—bone cancer	0.000102	0.00829	CcSEcCtD
Salicylic acid—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000101	0.00606	CbGpPWpGaD
Salicylic acid—ALB—Folate Metabolism—DHFR—bone cancer	0.0001	0.00602	CbGpPWpGaD
Salicylic acid—Weight increased—Doxorubicin—bone cancer	0.0001	0.00816	CcSEcCtD
Salicylic acid—Epistaxis—Epirubicin—bone cancer	9.99e-05	0.00815	CcSEcCtD
Salicylic acid—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	9.95e-05	0.00596	CbGpPWpGaD
Salicylic acid—Drowsiness—Doxorubicin—bone cancer	9.8e-05	0.008	CcSEcCtD
Salicylic acid—Erythema multiforme—Methotrexate—bone cancer	9.61e-05	0.00784	CcSEcCtD
Salicylic acid—Hepatitis—Epirubicin—bone cancer	9.51e-05	0.00776	CcSEcCtD
Salicylic acid—Tinnitus—Methotrexate—bone cancer	9.48e-05	0.00773	CcSEcCtD
Salicylic acid—Epistaxis—Doxorubicin—bone cancer	9.25e-05	0.00754	CcSEcCtD
Salicylic acid—SLC22A11—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.16e-05	0.00549	CbGpPWpGaD
Salicylic acid—Diarrhoea—Cisplatin—bone cancer	9e-05	0.00734	CcSEcCtD
Salicylic acid—Erythema multiforme—Epirubicin—bone cancer	8.99e-05	0.00733	CcSEcCtD
Salicylic acid—SLC16A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.98e-05	0.00539	CbGpPWpGaD
Salicylic acid—Tinnitus—Epirubicin—bone cancer	8.87e-05	0.00723	CcSEcCtD
Salicylic acid—Erythema—Methotrexate—bone cancer	8.85e-05	0.00722	CcSEcCtD
Salicylic acid—Hepatitis—Doxorubicin—bone cancer	8.8e-05	0.00718	CcSEcCtD
Salicylic acid—ALB—Platelet degranulation—SPARC—bone cancer	8.79e-05	0.00527	CbGpPWpGaD
Salicylic acid—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.73e-05	0.00523	CbGpPWpGaD
Salicylic acid—Dysgeusia—Methotrexate—bone cancer	8.66e-05	0.00707	CcSEcCtD
Salicylic acid—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	8.38e-05	0.00502	CbGpPWpGaD
Salicylic acid—Vomiting—Cisplatin—bone cancer	8.37e-05	0.00682	CcSEcCtD
Salicylic acid—Erythema multiforme—Doxorubicin—bone cancer	8.32e-05	0.00679	CcSEcCtD
Salicylic acid—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.31e-05	0.00498	CbGpPWpGaD
Salicylic acid—Rash—Cisplatin—bone cancer	8.3e-05	0.00677	CcSEcCtD
Salicylic acid—Dermatitis—Cisplatin—bone cancer	8.29e-05	0.00676	CcSEcCtD
Salicylic acid—Erythema—Epirubicin—bone cancer	8.28e-05	0.00675	CcSEcCtD
Salicylic acid—Tinnitus—Doxorubicin—bone cancer	8.21e-05	0.00669	CcSEcCtD
Salicylic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	8.14e-05	0.00488	CbGpPWpGaD
Salicylic acid—Dysgeusia—Epirubicin—bone cancer	8.11e-05	0.00661	CcSEcCtD
Salicylic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	8.11e-05	0.00486	CbGpPWpGaD
Salicylic acid—SLC22A11—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.91e-05	0.00474	CbGpPWpGaD
Salicylic acid—Nausea—Cisplatin—bone cancer	7.82e-05	0.00637	CcSEcCtD
Salicylic acid—SLC16A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.75e-05	0.00465	CbGpPWpGaD
Salicylic acid—Erythema—Doxorubicin—bone cancer	7.66e-05	0.00625	CcSEcCtD
Salicylic acid—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.56e-05	0.00454	CbGpPWpGaD
Salicylic acid—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.51e-05	0.0045	CbGpPWpGaD
Salicylic acid—Dysgeusia—Doxorubicin—bone cancer	7.5e-05	0.00612	CcSEcCtD
Salicylic acid—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.41e-05	0.00445	CbGpPWpGaD
Salicylic acid—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	7.33e-05	0.00439	CbGpPWpGaD
Salicylic acid—Confusional state—Methotrexate—bone cancer	7.28e-05	0.00594	CcSEcCtD
Salicylic acid—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.17e-05	0.0043	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—NDUFA12—bone cancer	7.02e-05	0.00421	CbGpPWpGaD
Salicylic acid—SLC22A8—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.98e-05	0.00419	CbGpPWpGaD
Salicylic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	6.97e-05	0.00418	CbGpPWpGaD
Salicylic acid—Anorexia—Methotrexate—bone cancer	6.88e-05	0.00561	CcSEcCtD
Salicylic acid—Confusional state—Epirubicin—bone cancer	6.81e-05	0.00556	CcSEcCtD
Salicylic acid—Oedema—Epirubicin—bone cancer	6.76e-05	0.00551	CcSEcCtD
Salicylic acid—Anorexia—Epirubicin—bone cancer	6.44e-05	0.00525	CcSEcCtD
Salicylic acid—Somnolence—Methotrexate—bone cancer	6.42e-05	0.00524	CcSEcCtD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.37e-05	0.00382	CbGpPWpGaD
Salicylic acid—Dyspepsia—Methotrexate—bone cancer	6.36e-05	0.00518	CcSEcCtD
Salicylic acid—Confusional state—Doxorubicin—bone cancer	6.3e-05	0.00514	CcSEcCtD
Salicylic acid—Decreased appetite—Methotrexate—bone cancer	6.28e-05	0.00512	CcSEcCtD
Salicylic acid—Oedema—Doxorubicin—bone cancer	6.25e-05	0.0051	CcSEcCtD
Salicylic acid—Pain—Methotrexate—bone cancer	6.18e-05	0.00504	CcSEcCtD
Salicylic acid—PTGS1—Biological oxidations—CYP3A4—bone cancer	6.15e-05	0.00369	CbGpPWpGaD
Salicylic acid—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.09e-05	0.00365	CbGpPWpGaD
Salicylic acid—SLC22A8—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.03e-05	0.00362	CbGpPWpGaD
Salicylic acid—Somnolence—Epirubicin—bone cancer	6.01e-05	0.0049	CcSEcCtD
Salicylic acid—Anorexia—Doxorubicin—bone cancer	5.96e-05	0.00486	CcSEcCtD
Salicylic acid—SLC16A1—Hemostasis—SPARC—bone cancer	5.96e-05	0.00357	CbGpPWpGaD
Salicylic acid—Feeling abnormal—Methotrexate—bone cancer	5.95e-05	0.00485	CcSEcCtD
Salicylic acid—Dyspepsia—Epirubicin—bone cancer	5.95e-05	0.00485	CcSEcCtD
Salicylic acid—AKR1C1—Signaling Pathways—GRM4—bone cancer	5.93e-05	0.00356	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—RGS1—bone cancer	5.93e-05	0.00356	CbGpPWpGaD
Salicylic acid—Decreased appetite—Epirubicin—bone cancer	5.87e-05	0.00479	CcSEcCtD
Salicylic acid—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.83e-05	0.0035	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—NT5C3A—bone cancer	5.82e-05	0.00349	CbGpPWpGaD
Salicylic acid—Pain—Epirubicin—bone cancer	5.78e-05	0.00471	CcSEcCtD
Salicylic acid—Constipation—Epirubicin—bone cancer	5.78e-05	0.00471	CcSEcCtD
Salicylic acid—Urticaria—Methotrexate—bone cancer	5.74e-05	0.00468	CcSEcCtD
Salicylic acid—Feeling abnormal—Epirubicin—bone cancer	5.57e-05	0.00454	CcSEcCtD
Salicylic acid—Somnolence—Doxorubicin—bone cancer	5.56e-05	0.00453	CcSEcCtD
Salicylic acid—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	5.52e-05	0.00331	CbGpPWpGaD
Salicylic acid—Dyspepsia—Doxorubicin—bone cancer	5.5e-05	0.00449	CcSEcCtD
Salicylic acid—AKR1C1—Disease—ENO2—bone cancer	5.46e-05	0.00327	CbGpPWpGaD
Salicylic acid—SLC16A1—Hemostasis—GNA11—bone cancer	5.45e-05	0.00327	CbGpPWpGaD
Salicylic acid—Decreased appetite—Doxorubicin—bone cancer	5.44e-05	0.00443	CcSEcCtD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.42e-05	0.00325	CbGpPWpGaD
Salicylic acid—Urticaria—Epirubicin—bone cancer	5.37e-05	0.00438	CcSEcCtD
Salicylic acid—Pain—Doxorubicin—bone cancer	5.35e-05	0.00436	CcSEcCtD
Salicylic acid—Constipation—Doxorubicin—bone cancer	5.35e-05	0.00436	CcSEcCtD
Salicylic acid—PTGS1—Biological oxidations—GSTP1—bone cancer	5.26e-05	0.00316	CbGpPWpGaD
Salicylic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	5.24e-05	0.00314	CbGpPWpGaD
Salicylic acid—Feeling abnormal—Doxorubicin—bone cancer	5.15e-05	0.0042	CcSEcCtD
Salicylic acid—AKR1C1—Signaling Pathways—GRM1—bone cancer	5.14e-05	0.00308	CbGpPWpGaD
Salicylic acid—Pruritus—Methotrexate—bone cancer	5.11e-05	0.00417	CcSEcCtD
Salicylic acid—AKR1C1—Disease—DHFR—bone cancer	5.06e-05	0.00304	CbGpPWpGaD
Salicylic acid—PTGS2—C-MYB transcription factor network—KIT—bone cancer	5.06e-05	0.00303	CbGpPWpGaD
Salicylic acid—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.03e-05	0.00302	CbGpPWpGaD
Salicylic acid—Urticaria—Doxorubicin—bone cancer	4.97e-05	0.00405	CcSEcCtD
Salicylic acid—SLC16A1—Hemostasis—IL3—bone cancer	4.94e-05	0.00296	CbGpPWpGaD
Salicylic acid—Diarrhoea—Methotrexate—bone cancer	4.94e-05	0.00403	CcSEcCtD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.93e-05	0.00296	CbGpPWpGaD
Salicylic acid—Pruritus—Epirubicin—bone cancer	4.78e-05	0.0039	CcSEcCtD
Salicylic acid—Dizziness—Methotrexate—bone cancer	4.78e-05	0.00389	CcSEcCtD
Salicylic acid—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	4.66e-05	0.00279	CbGpPWpGaD
Salicylic acid—Diarrhoea—Epirubicin—bone cancer	4.62e-05	0.00377	CcSEcCtD
Salicylic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	4.6e-05	0.00276	CbGpPWpGaD
Salicylic acid—Vomiting—Methotrexate—bone cancer	4.59e-05	0.00374	CcSEcCtD
Salicylic acid—AKR1C1—Metabolism—ENO2—bone cancer	4.57e-05	0.00274	CbGpPWpGaD
Salicylic acid—Rash—Methotrexate—bone cancer	4.55e-05	0.00371	CcSEcCtD
Salicylic acid—Dermatitis—Methotrexate—bone cancer	4.55e-05	0.00371	CcSEcCtD
Salicylic acid—Headache—Methotrexate—bone cancer	4.52e-05	0.00369	CcSEcCtD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	4.52e-05	0.00271	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.49e-05	0.00269	CbGpPWpGaD
Salicylic acid—Dizziness—Epirubicin—bone cancer	4.47e-05	0.00364	CcSEcCtD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.43e-05	0.00266	CbGpPWpGaD
Salicylic acid—Pruritus—Doxorubicin—bone cancer	4.42e-05	0.00361	CcSEcCtD
Salicylic acid—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.41e-05	0.00264	CbGpPWpGaD
Salicylic acid—Vomiting—Epirubicin—bone cancer	4.3e-05	0.0035	CcSEcCtD
Salicylic acid—Nausea—Methotrexate—bone cancer	4.29e-05	0.0035	CcSEcCtD
Salicylic acid—Diarrhoea—Doxorubicin—bone cancer	4.28e-05	0.00349	CcSEcCtD
Salicylic acid—Rash—Epirubicin—bone cancer	4.26e-05	0.00348	CcSEcCtD
Salicylic acid—Dermatitis—Epirubicin—bone cancer	4.26e-05	0.00347	CcSEcCtD
Salicylic acid—AKR1C1—Metabolism—DHFR—bone cancer	4.24e-05	0.00254	CbGpPWpGaD
Salicylic acid—Headache—Epirubicin—bone cancer	4.23e-05	0.00345	CcSEcCtD
Salicylic acid—Dizziness—Doxorubicin—bone cancer	4.13e-05	0.00337	CcSEcCtD
Salicylic acid—PTGS2—Spinal Cord Injury—CDK4—bone cancer	4.09e-05	0.00246	CbGpPWpGaD
Salicylic acid—Nausea—Epirubicin—bone cancer	4.01e-05	0.00327	CcSEcCtD
Salicylic acid—Vomiting—Doxorubicin—bone cancer	3.98e-05	0.00324	CcSEcCtD
Salicylic acid—AKR1C1—Metabolism—GNA11—bone cancer	3.96e-05	0.00238	CbGpPWpGaD
Salicylic acid—Rash—Doxorubicin—bone cancer	3.94e-05	0.00322	CcSEcCtD
Salicylic acid—Dermatitis—Doxorubicin—bone cancer	3.94e-05	0.00321	CcSEcCtD
Salicylic acid—Headache—Doxorubicin—bone cancer	3.92e-05	0.00319	CcSEcCtD
Salicylic acid—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	3.9e-05	0.00234	CbGpPWpGaD
Salicylic acid—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	3.85e-05	0.00231	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	3.84e-05	0.0023	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.76e-05	0.00225	CbGpPWpGaD
Salicylic acid—Nausea—Doxorubicin—bone cancer	3.71e-05	0.00303	CcSEcCtD
Salicylic acid—PTGS1—Metabolism—NDUFA12—bone cancer	3.69e-05	0.00221	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—TGFBR2—bone cancer	3.67e-05	0.0022	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—SMO—bone cancer	3.62e-05	0.00217	CbGpPWpGaD
Salicylic acid—AKR1C1—Metabolism—CYP3A4—bone cancer	3.59e-05	0.00215	CbGpPWpGaD
Salicylic acid—AKR1C1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.57e-05	0.00214	CbGpPWpGaD
Salicylic acid—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	3.57e-05	0.00214	CbGpPWpGaD
Salicylic acid—PTGS2—Spinal Cord Injury—RB1—bone cancer	3.56e-05	0.00213	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.5e-05	0.0021	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—GNA11—bone cancer	3.31e-05	0.00199	CbGpPWpGaD
Salicylic acid—SLC16A1—Hemostasis—PLAU—bone cancer	3.24e-05	0.00194	CbGpPWpGaD
Salicylic acid—CYP2C9—Biological oxidations—CYP3A4—bone cancer	3.23e-05	0.00194	CbGpPWpGaD
Salicylic acid—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	3.23e-05	0.00194	CbGpPWpGaD
Salicylic acid—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	3.19e-05	0.00191	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.18e-05	0.00191	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.14e-05	0.00188	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—ATF1—bone cancer	3.08e-05	0.00185	CbGpPWpGaD
Salicylic acid—AKR1C1—Metabolism—GSTP1—bone cancer	3.07e-05	0.00184	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—NT5C3A—bone cancer	3.06e-05	0.00183	CbGpPWpGaD
Salicylic acid—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.03e-05	0.00182	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—IL3—bone cancer	3e-05	0.0018	CbGpPWpGaD
Salicylic acid—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	2.99e-05	0.0018	CbGpPWpGaD
Salicylic acid—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	2.98e-05	0.00179	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—NDUFA12—bone cancer	2.93e-05	0.00176	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.78e-05	0.00167	CbGpPWpGaD
Salicylic acid—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.77e-05	0.00166	CbGpPWpGaD
Salicylic acid—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	2.73e-05	0.00164	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.66e-05	0.0016	CbGpPWpGaD
Salicylic acid—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.65e-05	0.00159	CbGpPWpGaD
Salicylic acid—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.62e-05	0.00157	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—TGFBR2—bone cancer	2.57e-05	0.00154	CbGpPWpGaD
Salicylic acid—PTGS2—Spinal Cord Injury—MMP9—bone cancer	2.57e-05	0.00154	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—ENO2—bone cancer	2.55e-05	0.00153	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—KIT—bone cancer	2.5e-05	0.0015	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—NT5C3A—bone cancer	2.43e-05	0.00145	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—IGF1R—bone cancer	2.42e-05	0.00145	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—NDUFA12—bone cancer	2.37e-05	0.00142	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—DHFR—bone cancer	2.36e-05	0.00142	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—BRAF—bone cancer	2.35e-05	0.00141	CbGpPWpGaD
Salicylic acid—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.29e-05	0.00137	CbGpPWpGaD
Salicylic acid—ALB—Folate Metabolism—TP53—bone cancer	2.24e-05	0.00134	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—GNA11—bone cancer	2.21e-05	0.00133	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—NDUFA12—bone cancer	2.08e-05	0.00124	CbGpPWpGaD
Salicylic acid—PTGS2—Spinal Cord Injury—EGFR—bone cancer	2.07e-05	0.00124	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.06e-05	0.00124	CbGpPWpGaD
Salicylic acid—ALB—Hemostasis—SPARC—bone cancer	2.01e-05	0.00121	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—CYP3A4—bone cancer	2e-05	0.0012	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.97e-05	0.00118	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—MDM2—bone cancer	1.97e-05	0.00118	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—NT5C3A—bone cancer	1.96e-05	0.00118	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—NDUFA12—bone cancer	1.94e-05	0.00116	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—PTGS2—bone cancer	1.9e-05	0.00114	CbGpPWpGaD
Salicylic acid—ALB—Hemostasis—GNA11—bone cancer	1.84e-05	0.0011	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.79e-05	0.00108	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—KIT—bone cancer	1.75e-05	0.00105	CbGpPWpGaD
Salicylic acid—PTGS2—Spinal Cord Injury—TP53—bone cancer	1.74e-05	0.00104	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—NT5C3A—bone cancer	1.72e-05	0.00103	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—GSTP1—bone cancer	1.71e-05	0.00103	CbGpPWpGaD
Salicylic acid—ALB—Hemostasis—IL3—bone cancer	1.67e-05	0.001	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—BRAF—bone cancer	1.65e-05	0.000988	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—NT5C3A—bone cancer	1.61e-05	0.000964	CbGpPWpGaD
Salicylic acid—AKR1C1—Metabolism—PTGS2—bone cancer	1.59e-05	0.000955	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.46e-05	0.000878	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.41e-05	0.000846	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.41e-05	0.000846	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—MDM2—bone cancer	1.38e-05	0.000828	CbGpPWpGaD
Salicylic acid—AKR1C1—Disease—EGFR—bone cancer	1.35e-05	0.000808	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—ENO2—bone cancer	1.34e-05	0.000803	CbGpPWpGaD
Salicylic acid—SLC16A1—Hemostasis—TP53—bone cancer	1.3e-05	0.000781	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.27e-05	0.000763	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—ENO2—bone cancer	1.27e-05	0.000761	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—DHFR—bone cancer	1.24e-05	0.000745	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—JUN—bone cancer	1.2e-05	0.00072	CbGpPWpGaD
Salicylic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.18e-05	0.00071	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—DHFR—bone cancer	1.18e-05	0.000706	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—MMP9—bone cancer	1.17e-05	0.0007	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—GNA11—bone cancer	1.16e-05	0.000696	CbGpPWpGaD
Salicylic acid—ALB—Hemostasis—PLAU—bone cancer	1.09e-05	0.000656	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—ENO2—bone cancer	1.06e-05	0.000637	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—CYP3A4—bone cancer	1.05e-05	0.000631	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.05e-05	0.000628	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1e-05	0.0006	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—DHFR—bone cancer	9.86e-06	0.000591	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—EGFR—bone cancer	9.44e-06	0.000566	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—GNA11—bone cancer	9.21e-06	0.000553	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—GSTP1—bone cancer	9e-06	0.00054	CbGpPWpGaD
Salicylic acid—SLC16A1—Metabolism—PTGS2—bone cancer	8.88e-06	0.000532	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—ENO2—bone cancer	8.6e-06	0.000516	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—TGFBR2—bone cancer	8.53e-06	0.000512	CbGpPWpGaD
Salicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.4e-06	0.000504	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—CYP3A4—bone cancer	8.35e-06	0.000501	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—DHFR—bone cancer	7.98e-06	0.000478	CbGpPWpGaD
Salicylic acid—AKR1C1—Signaling Pathways—TP53—bone cancer	7.92e-06	0.000475	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—ENO2—bone cancer	7.53e-06	0.000452	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—GNA11—bone cancer	7.45e-06	0.000447	CbGpPWpGaD
Salicylic acid—PTGS2—Metabolism—GSTP1—bone cancer	7.14e-06	0.000428	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—ENO2—bone cancer	7.04e-06	0.000422	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—DHFR—bone cancer	6.99e-06	0.000419	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—CYP3A4—bone cancer	6.76e-06	0.000405	CbGpPWpGaD
Salicylic acid—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.72e-06	0.000403	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—GNA11—bone cancer	6.53e-06	0.000392	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—DHFR—bone cancer	6.53e-06	0.000392	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—GNA11—bone cancer	6.1e-06	0.000366	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—CYP3A4—bone cancer	5.92e-06	0.000355	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—KIT—bone cancer	5.82e-06	0.000349	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—GSTP1—bone cancer	5.78e-06	0.000347	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—CYP3A4—bone cancer	5.53e-06	0.000332	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.5e-06	0.00033	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—BRAF—bone cancer	5.47e-06	0.000328	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—GSTP1—bone cancer	5.06e-06	0.000304	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—GSTP1—bone cancer	4.73e-06	0.000284	CbGpPWpGaD
Salicylic acid—PTGS1—Metabolism—PTGS2—bone cancer	4.66e-06	0.00028	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—MDM2—bone cancer	4.58e-06	0.000275	CbGpPWpGaD
Salicylic acid—ALB—Hemostasis—TP53—bone cancer	4.4e-06	0.000264	CbGpPWpGaD
Salicylic acid—PTGS2—Disease—EGFR—bone cancer	3.13e-06	0.000188	CbGpPWpGaD
Salicylic acid—ALB—Metabolism—PTGS2—bone cancer	2.99e-06	0.00018	CbGpPWpGaD
Salicylic acid—ABCB1—Metabolism—PTGS2—bone cancer	2.62e-06	0.000157	CbGpPWpGaD
Salicylic acid—CYP2C9—Metabolism—PTGS2—bone cancer	2.45e-06	0.000147	CbGpPWpGaD
